Cargando…

Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV

OBJECTIVES: To evaluate the effects of concomitant efavirenz-based ART and genetic polymorphism on the variability in rifampicin and 25-desacetylrifampicin pharmacokinetics. PATIENTS AND METHODS: Plasma concentrations of rifampicin and 25-desacetylrifampicin from 63 patients coinfected with TB and H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sundell, Jesper, Bienvenu, Emile, Äbelö, Angela, Ashton, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521403/ https://www.ncbi.nlm.nih.gov/pubmed/34337654 http://dx.doi.org/10.1093/jac/dkab258

Ejemplares similares

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
por: Wang, Tongtong, et al.
Publicado: (2023)

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011)

Prevalence of rifampicin resistance tuberculosis among HIV/TB coinfected patients in Benue State, Nigeria
por: Ejeh, Francis Enenche, et al.
Publicado: (2021)

Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients
por: Aklillu, Eleni, et al.
Publicado: (2020)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
por: Shu, Yuanlu, et al.
Publicado: (2021)

Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART
por: Rawizza, Holly E, et al.
Publicado: (2020)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients
por: Fox, D, et al.
Publicado: (2010)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping
por: Gausi, Kamunkhwala, et al.
Publicado: (2020)

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
por: Uttayamakul, Sumonmal, et al.
Publicado: (2010)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients
por: Nardotto, Glauco Henrique Balthazar, et al.
Publicado: (2021)

Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda
por: Habimana, Dominique Savio, et al.
Publicado: (2021)

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
por: Stott, K E, et al.
Publicado: (2018)

HIV/HPV coinfection: state-of-the-art
por: Buonaguro, Franco M
Publicado: (2010)

Incidence of socially significant infectious diseases (HIV, TB and HIV/TB coinfection) in the Arctic regions of Russia)
por: Zagdyn, Z., et al.
Publicado: (2021)

Elevated Notch ligands in serum are associated with HIV/TB coinfection
por: Bermick, Jennifer R., et al.
Publicado: (2021)

The Medication Experience of TB/HIV Coinfected Patients: Qualitative Study
por: de Resende, Natália Helena, et al.
Publicado: (2022)

Efavirenz, dysrhythmia and HIV
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

High Prevalence of Rifampicin Resistance Associated with Rural Residence and Very Low Bacillary Load among TB/HIV-Coinfected Patients at the National Tuberculosis Treatment Center in Uganda
por: Baluku, Joseph Baruch, et al.
Publicado: (2020)

HIV Is Associated with Modified Humoral Immune Responses in the Setting of HIV/TB Coinfection
por: van Woudenbergh, Esther, et al.
Publicado: (2020)

HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis
por: Loiseau, Chloé, et al.
Publicado: (2020)

Clinico-epidemiological profile of HIV/TB coinfected patients in Vadodara, Gujarat
por: Ghiya, Ragini, et al.
Publicado: (2009)

Systems biology approaches to investigate the role of granulomas in TB-HIV coinfection
por: Hoerter, Alexis, et al.
Publicado: (2022)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Effect of TB Treatment on Neutrophil-Derived Soluble Inflammatory Mediators in TB Patients with and without HIV Coinfection
por: Sitoe, Nádia, et al.
Publicado: (2023)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Potential Function of Granulysin, Other Related Effector Molecules and Lymphocyte Subsets in Patients with TB and HIV/TB Coinfection
por: Pitabut, Nada, et al.
Publicado: (2013)

1505. Clinical characterization of TB/HIV naive coinfection patients enrolled in a TB program in Cali - Colombia.
por: Muñoz-Lombo, Jenny Patricia, et al.
Publicado: (2023)

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
por: Dhoro, Milcah, et al.
Publicado: (2015)

Determination of dehydroepiandrosterone and its biologically active oxygenated metabolites in human plasma evinces a hormonal imbalance during HIV-TB coinfection
por: Vecchione, María Belén, et al.
Publicado: (2018)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients
por: Wanchu, A, et al.
Publicado: (2002)

Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda
por: Hermans, Sabine M, et al.
Publicado: (2017)

Tuberculosis Treatment Outcome in Patients with TB-HIV Coinfection in Kuala Lumpur, Malaysia
por: Selimin, Diana Safraa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h7vdabujt0njc78m71mufhj8rb